Back
 APD  Vol.8 No.1 , February 2019
Usefulness of Enteral Nutritional Intake Containing Median-Chain Fatty Acids in Parkinson’s Disease Patients with Weight Loss: A Pilot Study
Abstract: Background: No solution has yet been found for the nutritional issues of Parkinson’s disease (PD) patients with weight loss, which affects their prognosis. The objective of the present study was to investigate whether a defined-formula diet rich in ω3 fatty acids improved nutrition through the effect of ghrelin in PD patients with weight loss. Method: Weight, serum total protein, albumin, lipids, serum ghrelin, serum acylghrelin, leptin, and the Unified Parkinson’s Disease Rating Scale were monitored for approximately 3 months in 11 subjects given a defined-formula diet rich in ω3 fatty acids for 3 months and 5 control subjects who received no such treatment. Results: No significant changes from baseline in serum ghrelin, acylghrelin, and leptin levels were noted after administration of the nutritional product. Meanwhile, compared with the control, changes from baseline in the levels of albumin and weight were significant after the nutritional therapy rich in ω3 fatty acids (P < 0.05). Conclusion: Administration of a medium-chain fatty acid-rich product has few effects on motor functions and activities of daily living in PD patients with weight loss, but it is expected to offer effective ghrelin-mediated nutritional improvement.
Cite this paper: Shiraishi, M. , Isahaya, K. and Hasegawa, Y. (2019) Usefulness of Enteral Nutritional Intake Containing Median-Chain Fatty Acids in Parkinson’s Disease Patients with Weight Loss: A Pilot Study. Advances in Parkinson's Disease, 8, 1-7. doi: 10.4236/apd.2019.81001.
References

[1]   Fereshtehnejad, S.M., Ghazi, L., Sadeghi, M., et al. (2014) Prevalence of Malnutrition in Patients with Parkinson’s Disease: A Comparative Study with Healthy Controls Using Mini Nutritional Assessment (MNA) Questionnaire. Journal of Parkinson’s Disease, 4, 473-481.
https://doi.org/10.3233/JPD-130323

[2]   Cersosimo, M.G., Raina, G.B., Pellene, L.A., et al. (2018) Weight Loss in Parkinson’s Disease: The Relationship with Motor Symptoms and Disease Progression. BioMed Research International, 9, Article ID: 9642524.
https://doi.org/10.1155/2018/9642524

[3]   Chen, H., Zhang, S.M., Hernán, M.A., Willett, W.C. and Ascherio, A. (2003) Weight Loss in Parkinson’s Disease. Annals of Neurology, 53, 676-679.
https://doi.org/10.1002/ana.10577

[4]   Evidente, V.G., Caviness, J.N., Adler, C.H., Gwinn-Hardy, K.A. and Pratley, R.E. (2001) Serum Leptin Concentrations and Satiety in Parkinson’s Disease Patients with and without Weight Loss. Movement Disorders, 16, 924-927.
https://doi.org/10.1002/mds.1165

[5]   Lorefält, B., Ganowiak, W., Pålhagen, S., et al. (2004) Factors of Importance for Weight Loss in Elderly Patients with Parkinson’s Disease. Acta Neurologica Scandinavica, 110, 180-187.
https://doi.org/10.1111/j.1600-0404.2004.00307.x

[6]   Bachmann, C.G. and Trenkwalder, C. (2006) Body Weight in Patients with Parkinson’s Disease. Movement Disorders, 21, 1824-1830.
https://doi.org/10.1002/mds.21068

[7]   Seminara, R.S., Jeet, C., Biswas, S., et al. (2018) The Neurocognitive Effects of Ghrelin-Induced Signaling on the Hippocampus: A Promising Approach to Alzheimer’s Disease. Cureus, 11, e3285.
https://doi.org/10.7759/cureus.3285

[8]   Eriksdotter, M., Vedin, I., Falahati, F., et al. (2015) Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer’s Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study. Journal of Alzheimer’s Disease, 48, 805-812.
https://doi.org/10.3233/JAD-150102

[9]   Fahn, S. and Elton, R., Members of the UPDRS Development Committee (1987) In: Fahn, S., Marsden, C.D., Calne, D.B. and Goldstein, M., Eds., Recent Developments in Parkinson’s Disease, Macmillan Healthcare Information, Florham Park, Vol. 2, 153-163.

[10]   Global Parkinson’s Disease Survey (GPDS) Steering Committee (2002) Factors Impacting on Quality of life in Parkinson’s Disease: Results from an International Survey. Movement Disorders, 17, 60-67.
https://doi.org/10.1002/mds.10010

[11]   Vardi, J., Oberman, Z., Rabey, I., et al. (1976) Weight Loss in Patients Treated Long-Term with Levodopa. Metabolic Aspects. Journal of the Neurological Sciences, 30, 33-40.
https://doi.org/10.1016/0022-510X(76)90253-7

[12]   Markus, H.S., Cox, M. and Tomkins, A.M. (1992) Raised Resting Energy Expenditure in Parkinson’s Disease and Its Relationship to Muscle Rigidity. ClinSci (Lond), 83, 199-204.

[13]   Carter, W.J. and Lynch, M.E. (1994) Comparison of the Effects of Salbutamol and Clenbuterol on Skeletal Muscle Mass and Carcass Composition in Senescent Rats. Metabolism, 43, 1119-1125.
https://doi.org/10.1016/0026-0495(94)90054-X

[14]   Caruso, J.F., Signorile, J.F., Perry, A.C., et al. (1995) The Effects of Albuterol and Isokinetic Exercise on the Quadriceps Muscle Group. Medicine & Science in Sports & Exercise, 27, 1471-1476.
https://doi.org/10.1249/00005768-199511000-00002

[15]   Martineau, L., Horan, M.A., Rothwell, N.J., et al. (1992) Salbutamol, Abeta 2-Adrenoceptor Agonist, Increases Skeletal Muscle Strength in Young Men. Clinical Science, 83, 615-621.

[16]   Macht, M., Gerlich, C., Ellgring, H., et al. (2007) Patient Education in Parkinson’s Disease: Formative Evaluation of a Standardized Programme in Seven European Countries. Patient Education and Counseling, 65, 245-252.
https://doi.org/10.1016/j.pec.2006.08.005

 
 
Top